T. Rowe Price reports 4.9% stake in Quest Diagnostics
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Quest Diagnostics Inc. (common stock).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Quest Diagnostics Inc. (common stock). The firm reports beneficial ownership of 5,428,244 shares, representing 4.9% of the class. It has sole voting power over 5,321,387 shares and sole dispositive power over 5,428,244 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Ownership of 5 percent or Less of a Class regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Quest Diagnostics (DGX) does T. Rowe Price Associates report owning?
What type of security in Quest Diagnostics (DGX) is reported in this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.